http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107865877-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b0d44338a9983e0302c286cb9d319ff9 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 |
| filingDate | 2016-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_685253980351b754f8ecf6867157fabf |
| publicationDate | 2018-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107865877-A |
| titleOfInvention | Orientin is preparing the application in treating prostate cancer medicine |
| abstract | The invention discloses Orientin to prepare the application in treating prostate cancer medicine, belongs to technical field of new application of medicine.The present invention is evaluated by external MTT antineoplastic activity and found, growths of the Orientin to human prostate cancer cell line ALVA, gpc 1,9L B and Du145 also has significant inhibitory action.Therefore, Orientin can be used to prepare antiprostate cancer, have good development prospect.Belong to first public for purposes of the Orientin of the present invention in treatment prostate cancer medicine is prepared, and it is unexpectedly strong for the inhibitory activity of prostate gland cancer cell. |
| priorityDate | 2016-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.